Intrinsically long-acting agents compared with long-acting chronoformulations

Blood Pressure Monitoring

Volumn 5, Issue SUPPL. 1, 2000, Pages

  Meredith, Peter A ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Amlodipine; Chronotherapy; Controlled onset extended release verapamil; Hypertension; Long acting antihypertensive drug; Nifedipine gastrointestinal therapeutic system; Telmisartan; Trough:peak ratio

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DILTIAZEM; HYDROCHLOROTHIAZIDE; LONG ACTING DRUG; NIFEDIPINE; TELMISARTAN; VERAPAMIL;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG CONCENTRATION; DRUG HALF LIFE; HUMAN; HYPERTENSION; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; WAKEFULNESS;

EID: 0033946788     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126097-200005001-00005     Document Type: Review

References (31)

1. 1 Meredith PA. How to evaluate the duration of blood pressure control: the trough : peak ratio and 24 h monitoring. J Cardiovasc Pharmacol 1998; 31 (suppl 2):S17-S21.
2. 2 Morgan T, Anderson A. How important is 24 h control of blood pressure? Drug Saf 1996; 15:243-248.
3. 3 Meredith PA. Organ protection and optimal blood pressure control. Am J Hypertens 1995; 8:59S-62S.
4. 4 Meredith PA. Implications of the links between hypertension and myocardial infarction for choice of drug therapy in patients with hypertension. Am Heart J 1996; 132:222-228.
5. 5 Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA. Meta analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79:1512-1516.
6. 6 Kelly-Hayes M, Wolf PA, Kase CS, Brand FN, McGuirk JM, D'Agostino RB, et al. Temporal pattern of stroke onset. Stroke 1995; 26:1343-1347.
7. 7 Meredith PA, Perloff D, Mancia G, Pickering T. Blood pressure variability and its implications for antihypertensive therapy. Blood Press 1995; 4:5-11.
8. 8 Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1995; 24:793-801.
9. 9 Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27:130-135.
10. 10 Kario K, Shimada K. Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Am J Hypertens 1997; 10:261-268.
11. 11 Devereux RB, Pickering TG. Relationship between the level, pattern and variability of ambulatory blood pressure and target organ damage in hypertension. J Hypertens 1991; 9 (suppl 8):S34-S38.
12. 12 Verdecchia P, Schillaci G, Guerriera M, Gatteschi C, Benemio G, Boldrini F, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81:528-536.
13. 13 Hansen KW, Christensen CK, Andersen PH, Pedersen MM, Christiansen JS, Mogensen CE. Ambulatory blood pressure in microalbuminuric type 1 diabetic patients. Kidney Int 1992; 41:847-854.
14. 14 Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, DeCesaris R, Fogari R, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95:1464-1470.
15. 15 Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157:2413-2446.
16. 16 Chalmers J, MacMahon S, Mancia G, Whitworth J, Belin L, Hansson L, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Clin Exp Hypertens 1999; 21:1009-1060.
17. 17 Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomised trial. Hot Study Group. Lancet 1998; 13:1755-1762.
18. 18 Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 (suppl 2): S19-S25.
19. 19 Meredith PA. Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. Am J Cardiol 1999; 84:7K-12K.
20. 20 Meredith PA, Elliott HL. FDA guidelines on trough : peak ratios in the evaluation of antihypertensive agents. United States Food and Drug Administration. J Cardiovasc Pharmacol 1994; 23 (suppl 5):S26-S30.
21. 21 Leenen FH. Regression of cardiac hypertrophy by 1,4 dihydropyridines in hypertensive patients. J Hypertens 1998; 16 (suppl):S9-S15.
22. 22 Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3:295-302.
23. 23 Carter BL. Optimizing delivery systems to tailor pharmacotherapy to cardiovascular circadian events. Am J Hosp Pharm 1998; 55 (suppl 3):17-23.
24. 24 White WB, Anders RJ, MacIntyre JM, Black HR, Sica DA. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Am J Cardiol 1995; 76:375-380.
25. 25 White WB, Black HR, Weber MA, Elliott WJ, Bryzinski B, Fakouhi TD. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol 1998; 81:424-431.
26. 26 Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. Controlled Clin Trials 1998; 19:370-390.
27. 27 Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Study population and treatment titration in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). J Hypertens 1998; 16:2113-2116.
28. 28 Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi TD. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina. Am J Cardiol 1999; 83:507-514.
29. 29 Leenen FH, Fourney A, Notman G, Tanner J. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41:83-88.
30. 30 Meredith PA. Achieving and assessing therapeutic coverage. In: Metry J-M, Meyer UA (editors). Drug regimen compliance: issues in clinical trial and patient management. Chichester, England: John Wiley and Son, Ltd; 1999. pp. 41-60.
31. 31 Smilde JG. A comparison of amlodipine and felodipine extended release in the treatment of hypertension at steady state and after two missed doses. Curr Ther Res Clin Exp 1997; 58:141-153.